Brokers Offer Predictions for Orchard Therapeutics plc’s Q1 2023 Earnings (NASDAQ:ORTX)

Orchard Therapeutics plc (NASDAQ:ORTXGet Rating) – Research analysts at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for Orchard Therapeutics in a research report issued on Monday, March 13th. Oppenheimer analyst H. Singh forecasts that the company will post earnings per share of ($1.50) for the quarter. The consensus estimate for Orchard Therapeutics’ current full-year earnings is ($16.13) per share. Oppenheimer also issued estimates for Orchard Therapeutics’ Q2 2023 earnings at ($1.22) EPS, Q3 2023 earnings at ($1.20) EPS, Q4 2023 earnings at ($1.18) EPS, FY2023 earnings at ($5.06) EPS, FY2024 earnings at ($0.77) EPS, FY2025 earnings at ($0.58) EPS and FY2026 earnings at $0.05 EPS.

Orchard Therapeutics Stock Performance

Shares of ORTX opened at $5.20 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.57 and a quick ratio of 3.57. Orchard Therapeutics has a one year low of $3.60 and a one year high of $8.88. The company has a 50-day simple moving average of $5.59 and a two-hundred day simple moving average of $4.92. The firm has a market capitalization of $65.88 million, a PE ratio of -0.46 and a beta of 0.88.

Hedge Funds Weigh In On Orchard Therapeutics

Several large investors have recently made changes to their positions in the business. Jane Street Group LLC increased its position in shares of Orchard Therapeutics by 64.6% during the fourth quarter. Jane Street Group LLC now owns 75,643 shares of the company’s stock valued at $28,000 after acquiring an additional 29,690 shares in the last quarter. Forefront Analytics LLC grew its position in Orchard Therapeutics by 64.8% in the 4th quarter. Forefront Analytics LLC now owns 164,894 shares of the company’s stock worth $61,000 after purchasing an additional 64,853 shares during the period. Bank of America Corp DE grew its position in Orchard Therapeutics by 130.8% in the 1st quarter. Bank of America Corp DE now owns 95,749 shares of the company’s stock worth $68,000 after purchasing an additional 54,270 shares during the period. Millennium Management LLC bought a new stake in Orchard Therapeutics in the 2nd quarter worth approximately $106,000. Finally, Mariner LLC bought a new stake in Orchard Therapeutics in the 4th quarter worth approximately $234,000. 44.08% of the stock is currently owned by hedge funds and other institutional investors.

About Orchard Therapeutics

(Get Rating)

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.

Featured Articles

Earnings History and Estimates for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with's FREE daily email newsletter.